Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 100 shares, a drop of 95.2% from the March 15th total of 2,100 shares. Based on an average daily volume of 100 shares, the short-interest ratio is currently 1.0 days. Currently, 0.0% of the shares of the stock are short sold.
Basilea Pharmaceutica Price Performance
Shares of Basilea Pharmaceutica stock remained flat at $51.00 during trading hours on Friday. The company has a 50-day moving average price of $53.04 and a two-hundred day moving average price of $52.84. The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10. Basilea Pharmaceutica has a fifty-two week low of $51.00 and a fifty-two week high of $54.00.
About Basilea Pharmaceutica
(
Get Free Report)
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
See Also
Before you consider Basilea Pharmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Basilea Pharmaceutica wasn't on the list.
While Basilea Pharmaceutica currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
